Ascletis Pharma Future Growth
Future criteria checks 0/6
Ascletis Pharma's earnings are forecast to decline at 4.1% per annum while its annual revenue is expected to grow at 117.7% per year. EPS is expected to decline by 3.5% per annum.
Key information
-4.1%
Earnings growth rate
-3.5%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 117.7% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 11 Oct 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 77 | -289 | N/A | N/A | 1 |
| 12/31/2025 | N/A | -298 | N/A | N/A | 1 |
| 12/31/2024 | N/A | -281 | N/A | N/A | 1 |
| 6/30/2024 | 10 | -258 | -299 | -280 | N/A |
| 3/31/2024 | 33 | -202 | -231 | -212 | N/A |
| 12/31/2023 | 57 | -145 | -163 | -144 | N/A |
| 9/30/2023 | 59 | -194 | -169 | -157 | N/A |
| 6/30/2023 | 62 | -243 | -173 | -171 | N/A |
| 3/31/2023 | 58 | -279 | -195 | -187 | N/A |
| 12/31/2022 | 54 | -315 | -217 | -202 | N/A |
| 9/30/2022 | 66 | -246 | -198 | -182 | N/A |
| 6/30/2022 | 79 | -176 | -179 | -161 | N/A |
| 3/31/2022 | 78 | -188 | -167 | -154 | N/A |
| 12/31/2021 | 77 | -199 | -154 | -147 | N/A |
| 9/30/2021 | 58 | -234 | -172 | -150 | N/A |
| 6/30/2021 | 40 | -269 | -190 | -153 | N/A |
| 3/31/2021 | 37 | -239 | -157 | -119 | N/A |
| 12/31/2020 | 35 | -209 | -124 | -85 | N/A |
| 9/30/2020 | 82 | -155 | -86 | -56 | N/A |
| 6/30/2020 | 130 | -100 | -47 | -28 | N/A |
| 3/31/2020 | 152 | -98 | -75 | -51 | N/A |
| 12/31/2019 | 173 | -96 | -103 | -74 | N/A |
| 9/30/2019 | 150 | -92 | -130 | -91 | N/A |
| 6/30/2019 | 127 | -89 | -157 | -107 | N/A |
| 3/31/2019 | 153 | -43 | -146 | -83 | N/A |
| 12/31/2018 | 166 | -7 | -157 | -97 | N/A |
| 9/30/2018 | 154 | -5 | -172 | -134 | N/A |
| 6/30/2018 | 142 | -2 | -188 | -171 | N/A |
| 3/31/2018 | 91 | -40 | N/A | -210 | N/A |
| 12/31/2017 | 53 | -54 | N/A | -198 | N/A |
| 12/31/2016 | 33 | -27 | N/A | -12 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2VJ is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2VJ is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2VJ is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2VJ is forecast to have no revenue next year.
High Growth Revenue: 2VJ is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 2VJ's Return on Equity is forecast to be high in 3 years time